Neovasc

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neovasc Inc. is a specialty medical device company that develops and manufactures products for the rapidly growing cardiovascular device marketplace.Neovasc Inc. offers pericardial tissue processing, vascular product development, design, and manufacturing solutions to industry partners.

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 11, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the second quarter ended June 30, 2022.Recent HighlightsGenerated revenues of $818,000, a quarterly record and a year-over-year increase of 29% over the second quarter of 2021.Advanced enrollment in the COSIRA II trial with 40 patients enrolled and 21 patients randomized across 10 sites.

Neovasc Announces Second Quarter Financial Results and Provides Corporate Update

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on August 11, 2022.

Neovasc to Report Second Quarter Financial Results on August 11, 2022

VANCOUVER and MINNEAPOLIS, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the United States Food and Drug Administration (“FDA”) has approved a protocol supplement to the COSIRA-II Investigational Device Exemption (“IDE”) Trial. The approval expands the number of patients eligible for treatment in the trial and adds two previously planned imaging sub-studies designed to provide insights into the safety and mechanism of action of the Neovasc Reducer™ (“Reducer”). The timing of the approval is ahead of the Company's internal target and will allow for additional patients to be treated.

Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations

Expansion Driven by NICE Guidelines and Enhanced Reimbursement for the Neovasc Reducer™

Neovasc Announces Direct Sales Operations in United Kingdom

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 8, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the 2022 Sidoti & Co. Summer Small Cap Virtual Investor Conference to be held June 15-16, 2022. Neovasc's Chief Operating Officer, Bill Little, will be presenting at 1:45 pm ET on Wednesday, June 15.The presentation can be accessed here. Additionally, a recording of the...

Neovasc to Participate in Sidoti & Co. Summer Small Cap Virtual Investor Conference

VANCOUVER and MINNEAPOLIS, May 23, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Neovasc, Inc.  (Neovasc or the Company) ( NASDAQ  ,  TSX  : NVCN) today announced that its management team will be participating in the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. Fred Colen, Neovasc's President and Chief Executive Officer, will be presenting at 11:00 am ET on Wednesday, May 25.

Neovasc to Participate in H.C. Wainwright Global Investment Conference

VANCOUVER and MINNEAPOLIS, May 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has received written notification from the Nasdaq Stock Market LLC (the “Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) pursuant to Nasdaq Listing Rule 5810 for continued listing on the Nasdaq.

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

Neovasc Inc. (NASDAQ:NVCN ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Mike Cavanaugh - Investor Relations Fred Colen - President and Chief Executive Officer Chris Clark - Chief Financial Officer Conference Call Participants Vernon Bernardino - H.C. Wainwright Operator Greetings and welcome to Neovasc First Quarter 2022 Earnings Conference Call.

Neovasc Inc. (NVCN) CEO Fred Colen on Q1 2022 Results - Earnings Call Transcript

Neovasc (NVCN) delivered earnings and revenue surprises of -140.80% and 23.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Neovasc (NVCN) Reports Q1 Loss, Misses Revenue Estimates

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 12, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the quarter ended March 31, 2022.Recent HighlightsAchieved Q1 revenue of approximately $611,000, an increase of 35% over the same period in 2021, delivering a record first quarter.Activated 6 sites, enrolled 21 patients, and, of those, randomized the first 4 patients, in the COSIRA II IDE trial for the...

Neovasc Announces First Quarter Financial Results and Provides Corporate Update

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 29, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended March 31, 2022 on Thursday, May 12, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on May 12, 2022.Interested parties may access the conference call by dialing (877) 407-9208...

Neovasc to Report First Quarter Financial Results on May 12, 2022

VANCOUVER, BC, April 27, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that the Company has filed articles of amendment, effective today, to effect the previously announced share consolidation (reverse stock split) (the “Consolidation”) of its issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every twenty-five (25) pre-Consolidation Common Shares. The Consolidation will reduce the number of Common Shares issued and outstanding from approximately 68,228,061 Common Shares to approximately 2,729,107 Common Shares. The Common Shares are expected to commence trading on the Toronto Stock Exchange (the “TSX”) and on the Nasdaq Capital Market (the “Nasdaq”) on a post-Consolidation basis on or about the opening of trading on April 29, 2022.

Neovasc Announces Effective Date of Share Consolidation

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 20, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX : NVCN) (Neovasc or the Company) today announced that its management team will be participating in the 2022 Bloom Burton & Co. Healthcare Investment Conference to be held May 2-3, 2022. Fred Colen, Neovasc's Chief Executive Officer, will be presenting at 4:00 pm ET on Monday, May 2.The presentation can be accessed here. Additionally, a recording of the presentation will be available...

Neovasc to Participate in Bloom Burton & Co. Healthcare Investment Conference

New York, New York--(Newsfile Corp. - April 13, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) "Neovasc" or the "Company") is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on April 12, 2022 in Vancouver, B.C. (the "Meeting").At the Meeting, the shareholders of the Company (the "Shareholders") re-elected board members Steven Rubin, Paul Geyer, Doug Janzen, Norman Radow, Alexei Marko and Fred Colen...

Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders

Vancouver, British Columbia--(Newsfile Corp. - March 24, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that, pursuant to a Restated Securities Purchase Agreement with Strul Medical Group LLC ("SMG"), on a private placement basis (the "Private Placement"), it has issued an amended...

Neovasc Announces Consolidation and Extension of Convertible Debt

Neovasc Inc.'s (NVCN) CEO Fred Colen on Q4 2021 Results - Earnings Call Transcript

VANCOUVER and MINNEAPOLIS, March 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2021.

Neovasc Announces Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update

VANCOUVER, Feb. 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on March 10, 2022.

Neovasc to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

VANCOUVER and MINNEAPOLIS, Feb. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the German Institute for the Hospital Remuneration System ("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation yet again for 2022.  Additionally, the Company announced the 500th patient has been treated in Germany.

Neovasc Announces German Reimbursement Renewal and Commercial Progress

VANCOUVER and MINNEAPOLIS, Feb. 04, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire  --  Neovasc, Inc.  (Neovasc or the Company) ( NASDAQ ,  TSX : NVCN) today announced the publication of cost-effectiveness studies supporting the use of the Neovasc  Reducer™ (“Reducer”).

Independent Publication Reports Neovasc Reducer™ Demonstrates Cost Savings

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 4, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced the publication of cost-effectiveness studies supporting the use of the Neovasc ReducerTM ("Reducer").The two analyses, authored by Americo Cicchetti, Graduate School of Health Economics and Management (ALTEMS) at the Catholic University of Sacro Cuore, Rome, included a budget impact analysis and a cost-utility analysis. The evaluations, both of which were positive for the Reducer therapy,...

Independent Publication Reports Neovasc Reducer(TM) Demonstrates Cost Savings

VANCOUVER and MINNEAPOLIS, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today announced the complete dismissal of the consolidated amended complaint in the shareholder class action case captioned In re Neovasc Inc. Securities Litigation, Case No. 7:20-cv-09313, filed in the United States District Court for the Southern District of New York.  The consolidated amended complaint was dismissed in its entirety with prejudice and without leave to amend.

Neovasc Announces Complete Dismissal of Securities Class Action Complaint with Prejudice

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 20, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced the publication of an article entitled, "The Effectiveness of CS Reducer for the Treatment of Refractory Angina - a Meta-Analysis" in the Canadian Journal of Cardiology.The article's lead author and senior authors are Aviram Hochstadt, M.D., and Maayan Konigstein, M.D., Sourasky Medical Center and the Sackler School of Medicine, Tel Aviv University, Tel...

Neovasc Announces Publication Supporting the Neovasc Reducer(TM) Device

VANCOUVER and MINNEAPOLIS, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “The Effectiveness of CS Reducer for the Treatment of Refractory Angina – a Meta-Analysis” in the Canadian Journal of Cardiology.

Neovasc Announces Publication Supporting the Neovasc Reducer™ Device

VANCOUVER and MINNEAPOLIS, Jan. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of a case series in the journal Cardiovascular Revascularization Medicine describing successful uses of the Neovasc Reducer™ (“Reducer”) under a compassionate use protocol in the United States. The patients were treated under the care of Ryan Gindi, M.D., and the procedures were performed by Gerald Koenig, M.D., Ph.D, both from the Division of Cardiology, Henry Ford Hospital, Detroit. Following the commencement of the COSIRA-II Trial in the United States, qualifying patients are now eligible to be treated in a clinical trial for the device.

News for Neovasc Stock (NVCN)